bioXXmed Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

bioXXmed's earnings have been declining at an average annual rate of -60.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.8% per year.

Anahtar bilgiler

-60.3%

Kazanç büyüme oranı

-47.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi-14.6%
Gelir büyüme oranı-14.8%
Özkaynak getirisi-19,469.0%
Net Marj-420,594.5%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

Jul 29
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

CytoTools AG (ETR:T5O): Are Analysts Optimistic?

May 12
CytoTools AG (ETR:T5O): Are Analysts Optimistic?

Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Jan 08
Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Gelir ve Gider Dağılımı

bioXXmed nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

XTRA:T5O Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-2100
31 Mar 240-2100
31 Dec 230-2100
30 Sep 230-1100
30 Jun 230-100
31 Mar 230-100
31 Dec 220-100
30 Sep 220-200
30 Jun 220-400
31 Mar 220-400
31 Dec 210-410
30 Sep 210-310
30 Jun 210-210
31 Mar 210-210
31 Dec 200-210
30 Sep 200-210
30 Jun 200-110
31 Mar 200-100
31 Dec 190-100
30 Sep 190-100
30 Jun 190-100
31 Mar 190-100
31 Dec 180-100
30 Sep 180-100
30 Jun 180-100
31 Mar 180-100
31 Dec 170-100
30 Sep 170-100
30 Jun 170-100
31 Mar 170-100
31 Dec 160-100
30 Sep 160-100
30 Jun 160-100
31 Mar 160-100
31 Dec 150-100
30 Sep 150-100
30 Jun 150-100
31 Mar 150-100
31 Dec 140-100
30 Sep 140-100
30 Jun 140-100
31 Mar 140-110
31 Dec 130-110

Kaliteli Kazançlar: T5O is currently unprofitable.

Büyüyen Kar Marjı: T5O is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: T5O is unprofitable, and losses have increased over the past 5 years at a rate of 60.3% per year.

Büyüme Hızlandırma: Unable to compare T5O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: T5O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Özkaynak Getirisi

Yüksek ROE: T5O has a negative Return on Equity (-19469.04%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin